A #genetherapy success story! Just amazing 🧬 #sicklecell

"declared the first from the US’s Gulf coast region to undergo gene editing therapy utilizing Casgevy’s CRISPR/Cas9 technology and be functionally cured of sickle cell disease"

https://www.theguardian.com/us-news/2026/jun/24/louisiana-man-sickle-cell-functionally-cured

"Truly evil" FDA rejection of gene therapy overturned after Trump official ousted

https://arstechnica.com/health/2026/06/truly-evil-fda-rejection-of-gene-therapy-overturned-after-trump-official-ousted/

#HealthTech #GeneTherapy #ScienceNews

Clinic booking ≠ gene therapy screening.

Evaluating advanced therapy review pathways in China requires a review-ready medical dossier—not just a standard clinic booking. Missing pathology records, incomplete treatment history, or poorly translated genetic reports can stop institutional review before it begins. MedBridgeNZ organizes medical records and molecular reports for administrative review-readiness.

#GeneTherapy #RareDisease #MedicalConcierge

The Pacemaker Patch

https://fed.brid.gy/r/https://hackaday.com/2026/06/13/the-pacemaker-patch/

Exploring advanced therapeutics abroad? Accessing gene therapy pathways in China requires precise record translation and strict institutional screening.

As a specialized medical concierge provider, MedBridgeNZ handles the complex logistics of Medical Tourism China—so you and your doctors can focus on the science.

Read our full guide on navigating these administrative pathways: https://zurl.co/u0AKU

#MedicalTourismChina #GeneTherapy #MedicalConcierge #MedBridgeNZ

#GeneTherapy #HeartDisease

"Gene therapies to fix failing hearts gain steam after years in the doldrums

Treatments aim to bulk up failing hearts to restore their vigour — but can the field move on from past controversy?

The first clinical trial aimed at growing new heart-muscle cells is now under way, and companies are developing at least four other regenerative gene therapies for heart conditions.

'These are the first-in-human studies to take regeneration into the clinic,' says Andrew Baker, a gene-therapy researcher at the University of Edinburgh, UK, who is unaffiliated with the efforts. 'It’s a very exciting time.'

But the excitement is tempered with caution. The mammalian heart is bad at repairing itself and 'is notoriously unwieldy when it comes to efforts to try to get it to regenerate', says Sean Wu, a cardiologist at Stanford University in California. Some scientists are unconvinced that the data underpinning the existing clinical trial show true regeneration in the form of cell division. And efforts to regenerate the heart are still haunted by a controversy that led to the retraction of at least a dozen papers and the closure of a high-profile laboratory.

Developing a gene therapy in this field will be difficult, says Antonio Abbate, a cardiologist at the University of Virginia in Charlottesville. But 'we have to do research because, eventually, we’ll get it right'"

https://archive.ph/UbQtS